Appili Therapeutics (APLIF) and its partner Vitalex Biosciences announced that the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded up to $40M in funding to support the development of VXV-01, a vaccine aimed at protecting against invasive fungal infections. The five-year contract consists of a 22-month base period of performance totalling $3.6M, with twelve additional option periods valued at approximately $36.3M for a total contract value of approximately $40M. Under the terms of the contract, Appili will partner with Vitalex to oversee a comprehensive development program for a Vitalex vaccine, VXV-01 that includes manufacturing, nonclinical studies, clinical and regulatory activities. The NIAID funds are expected to support the development of VXV-01 through Investigational New Drug submission and completion of Phase 1 clinical trials. Vitalex is the current owner of VXV-01, and as a condition to advancing the program, Appili and Vitalex expect to enter into an agreement for the development of VXV-01.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLIF:
- Appili Therapeutics Secures Shareholder Approval for Strategic Initiatives
- Appili Therapeutics to Showcase Tularemia Vaccine at NATO Conference
- Appili Therapeutics to present progress on Tularemia vaccine
- Appili Therapeutics Strengthens Biodefense Partnerships and Advances Drug Development
- Appili Therapeutics, colleagues publish manuscript on ATI-1701 efficacy